Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales milestone payment to Basilea
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, January 07, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced today that sales of the antifungal Cresemba® (isavuconazole) by its partner Astellas Pharma Inc. (“Astellas”) in the United States exceeded the threshold triggering a milestone payment to Basilea of CHF 15 million.
David Veitch, Chief Executive Officer of Basilea, said: “We are very pleased with the continued commercial success of Cresemba. This significant milestone payment reflects the strong sales growth in 2021 in the U.S. and confirms the important role that Cresemba plays in the treatment of patients suffering from invasive mold infections.”
Under the license agreement with Astellas, Basilea is entitled to receive milestone payments based on Astellas exceeding certain net sales thresholds in the United States within a calendar year. Total sales milestone payments from Astellas, including the CHF 15 million triggered now, amount to CHF 30 million and Basilea is still eligible for additional sales milestone payments of up to CHF 260 million, in addition to tiered, double-digit royalties on U.S. sales.
Cresemba has been approved in more than 60 countries to date and is currently marketed in 56 countries, including the United States, most EU member states and additional countries inside and outside of Europe. In the twelve months between October 2020 and September 2021, total in-market sales of Cresemba amounted to more than USD 300 million, a 26.5 percent growth year-on-year.1
About isavuconazole (Cresemba)
Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. Basilea has entered into several license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa region, Canada, Russia, Turkey and Israel. Cresemba is approved in the United States for patients 18 years of age and older for the treatment of invasive aspergillosis and invasive mucormycosis.2 Cresemba is also approved in the European Union and several additional countries in Europe and beyond.3 It has orphan drug designation in the U.S., Europe and Australia for its approved indications.
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with cancer and infectious diseases. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have several preclinical assets in both cancer and infectious diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
|Peer Nils Schröder, PhD|
Head of Corporate Communications & Investor Relations
|Phone||+41 61 606 1102|
This ad hoc announcement can be downloaded from www.basilea.com.
- IQVIA, September 2021. In-market sales reported as moving annual total (MAT) in U.S. dollar.
- Cresemba U.S. prescribing information [Accessed: January 06, 2022]
- The registration status and approved indications may vary from country to country.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Bombardier Announces Firm Order for the First Challenger 3500 Business Jet based in Europe for Charter Operations with Air Corporate SRL8.8.2022 14:00:00 CEST | Press release
Italian-based Air Corporate SRL to be the first European operator to offer the Challenger 3500 business jet for charter services, which will join the company’s fleet of aircraft With its innovative technology, redesigned cabin and sustainably minded features, the Challenger 3500 business jet is ideally suited for the European charter market MONTREAL, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Bombardier today announced the sale of its industry-leading Challenger3500 business jet to Italian-based operator, Air Corporate SRL. This will be the first company to offer the aircraft for charter in Europe. Introduced in 2021, the new Challenger 3500 aircraft offers a unique blend of performance, advantageous operating costs, ultimate cabin experience and smooth ride, making it an ideal choice for the European charter market. And with its redesigned interior with intelligent and sustainably minded cabin features, the Challenger 3500 aircraft is elegantly crafted to combine comfort with function, fully e
RCI Banque: the " Half-Yearly Financial Report 2022" is now available one the website8.8.2022 11:54:30 CEST | Press release
August 8th, 2022 The "EMTN Semi-Annual Report 2022" is now available on the website www.mobilize-fs.com Attachment RCI Banque_Financial Report (emtn) 06.2022
RCI Banque: The EMTN Semi-Anual Report 2022 is now available8.8.2022 11:49:31 CEST | Press release
August 8th,2022 "The EMTN Semi-Annual Report 2022" is now available on the website www.mobilize-fs.com Attachment Communiqué de publication - The emtn semi annnual report 2022 is now available
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme8.8.2022 11:45:00 CEST | Press release
Company Announcement No. 49/2022 Copenhagen, 8 Aug 2022 Transactions in connection with share buy-back programme On 19 May 2022, Scandinavian Tobacco Group A/S announced that the share buy-back programme that was initiated 9 March 2022 was increased to an aggregated value of up to DKK 1,000 million. The purpose of the programme is to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. Part of the buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 35/2022. The share buy-back programme will end no later than 28 February 2023. The fo
Maha Energy AB enters into a Farmout Agreement with Mafraq Energy LLC for Block 70 in Oman8.8.2022 11:00:00 CEST | Press release
Maha Energy AB (publ) (“Maha” or the “Company”), through its wholly owned subsidiary Maha Energy (Oman) Ltd., has entered into an Agreement with Mafraq Energy LLC for Maha to reduce the Participating Interest in the Block 70 Exploration and Production Sharing Agreement (“EPSA”) in Oman from 100% to 65%. Maha will continue to be the Operator of the Block. The Agreement is subject to Government approval in Oman. Maha has decided to reduce its working interest in the onshore oil-bearing Block 70 in Oman by bringing in a strategic Omani partner. The Agreement requires Mafraq Energy LLC to reimburse Maha for their prorated share of all past costs including the signature bonus. Mafraq Energy LLC will also be required to pay their share of all future expenditures on Block 70. Jonas Lindvall, Maha’s CEO said: “We are delighted to have Mafraq Energy LLC join us on Block 70. Mafraq Energy LLC brings extensive experience of the Mafraq field and the surrounding areas in Oman. The fact that Mafraq